Clinical Trials Browser

Disease Progression × Cetuximab × 90 days × Clear all

NCT04017650 2026-05-22

Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer

Phase 1/2 Active not recruiting

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Disease Progression